Neogenomics (NEO) Cash from Investing Activities (2010 - 2026)

Neogenomics has reported Cash from Investing Activities for 17 years, with the latest figure at -$5.0 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities fell 240.45% year-over-year to -$5.0 million; the trailing twelve-month figure through Mar 2026 stood at -$20.9 million (down 1205.61% YoY), and the FY2025 full-year result was -$12.3 million, down 195.96% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$5.0 million, up from -$6.3 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $23.7 million in Q1 2023, with the low at -$9.3 million in Q2 2025.
• Historically, Cash from Investing Activities has averaged $4.3 million across 5 years, with a median of -$277000.0 in 2025.
• Annual changes were most pronounced in 2023 — Cash from Investing Activities surged 1717.59% — and 2026, when it plunged 240.45%.
• Neogenomics' Cash from Investing Activities stood at -$1.1 million in 2022, then surged by 1717.59% to $17.2 million in 2023, then plunged by 131.79% to -$5.5 million in 2024, then decreased by 15.33% to -$6.3 million in 2025, then increased by 20.7% to -$5.0 million in 2026.
• The last three Cash from Investing Activities figures came in at -$5.0 million (Q1 2026), -$6.3 million (Q4 2025), and -$277000.0 (Q3 2025), per Business Quant data.